BCAL vs BUI

BCAL exhibits a weak financial health profile with a Piotroski F-Score of 3/9, indicating significant concerns in profitability, leverage, and operating efficiency. Despite this, the company shows strong revenue growth (198.3% YoY) and solid earnings surprises in recent quarters, suggesting improving operational momentum. Valuation appears reasonable relative to peers with a P/E of 8.72 versus sector average of 20.71, though the lack of Altman Z-Score and incomplete balance sheet data limits confidence in financial stability. The stock trades above the Graham Number ($28.75) but below analyst target ($21.83), creating a mixed value signal.

The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 1/9, indicating weak fundamental strength. Despite a low P/E of 6.22 compared to the sector average of 30.89 and a high dividend yield of 6.14%, profitability metrics are entirely absent (0.00% margins), and critical financial data is missing, raising transparency issues. The technical trend is deeply bearish at 10/100, and insider sentiment is weak at 40/100, further undermining confidence. While historical price performance shows strong 3Y and 5Y gains, the lack of financial disclosures and extremely poor health metrics suggest elevated risk.